MYCOSIS FUNGOIDES
Clinical trials for MYCOSIS FUNGOIDES explained in plain language.
Never miss a new study
Get alerted when new MYCOSIS FUNGOIDES trials appear
Sign up with your email to follow new studies for MYCOSIS FUNGOIDES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug aims to shrink tumors in Hard-to-Treat skin cancer
Disease control Not yet recruitingThis study tests a new drug, VG712, in people with a rare type of skin lymphoma called mycosis fungoides that has not responded to at least two prior treatments. The drug works by targeting and killing certain immune cells that drive the disease. About 386 adults will be randomly…
Matched conditions: MYCOSIS FUNGOIDES
Phase: PHASE2 • Sponsor: Virogen Biotechnology Inc. • Aim: Disease control
Last updated May 26, 2026 04:12 UTC
-
New antibody targets Hard-to-Treat skin cancer in first human trial
Disease control Not yet recruitingThis early-phase trial tests a new drug, DT-7012, for people with advanced cutaneous T-cell lymphoma (CTCL) that has not responded to other treatments. The drug is an antibody designed to seek out and destroy cancer cells in the skin while also helping the immune system fight the…
Matched conditions: MYCOSIS FUNGOIDES
Phase: EARLY_PHASE1 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated May 18, 2026 12:09 UTC